Gynecologic and Obstetric Investigation
Original Article
CA125 and HE4: Measurement Tools for Ovarian CancerZhao T.a · Hu W.baAnhui Provincial Hospital Affiliated to Anhui Medical University, and bObstetrics and Gynecology, Anhui Provincial Hospital, Hefei, Anhui Province, China
Keywords: Molecular markersCA125Ovarian cancerHE4 |
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: August 31, 2015
Accepted: November 05, 2015
Published online: April 29, 2016
Issue release date: September 2016
Number of Print Pages: 6
Number of Figures: 3
Number of Tables: 3
ISSN: 0378-7346 (Print)
eISSN: 1423-002X (Online)
For additional information: https://www.karger.com/GOI
Abstract
Aims: This study aimed to examine the clinical significance of carbohydrate antigen 125 (CA125) and human epididymis protein 4 (HE4) serum levels in combination for ovarian cancer detection in patients. Methods: In total, 75 patients with ovarian cancer, 86 patients with benign ovarian tumors, 75 patients with endometriosis and 34 healthy women (as a control group) were selected from January 2012 to July 2015 at Anhui province hospitals. The sensitivity and specificity of detection of CA125, HE4 and combined CA125 + HE4 in serum were analyzed for each group. Results: HE4 and CA125 serum levels in the ovarian cancer group were higher than those in the other 3 groups (p < 0.001). The sensitivity of CA125 was higher than that of HE4 (88.2 vs. 54.7%, respectively), whereas the specificity of HE4 was higher than that of CA125 (97.9 vs. 67.4%, respectively). In contrast, the sensitivity and specificity of HE4 combined with CA125 were 82.7 and 91.4%, respectively. The receiver operating characteristic-area under the curve values of HE4, CA125 and HE4 + CA125 were 0.889, 0.893 and 0.925, respectively. Conclusions: Combined detection of CA125 with HE4 can improve the sensitivity and specificity of ovarian cancer diagnosis and has certain clinical significance that can guide treatment planning.
© 2016 S. Karger AG, Basel
Related Articles:
References
- Siegel R, et al: Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
- Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
- Menon U, Jacobs IJ: Ovarian cancer screening in the general population: current status. Int J Gynecol Cancer 2001;11(suppl 1):3-6.
- Rein BJ, Gupta S, Dada R, Safi J, Michener C, Agarwal A: Potential markers for detection and monitoring of ovarian cancer. J Oncol 2011;2011:475983.
- Ortiz-Muñoz B, Aznar-Oroval E, García García A, Covisa Peris A, Perez Ballestero P, Sanchez Yepes M, Garcia Lozano T, Illueca Ballester C, García Garcia E: HE4, CA125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer. Tumour Biol 2014;35:7249-7258.
- Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, et al: New tumor markers: CA125 and beyond. Int J Gynecol Cancer 2005;15(suppl 3):274-281.
- van Nagell JR Jr, DePriest PD, Ueland FR, DeSimone CP, Cooper AL, McDonald JM, et al: Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. Cancer 2007;109:1887-1896.
- Rauh-Hain JA, Krivak TC, del Carmen MG, Olawaiye AB: Ovarian cancer screening and early detection in the general population. Rev Obstet Gynecol 2011;4:15-21.
- Nagy B Jr, Krasznai ZT, Balla H, Csobán M, Antal-Szalmás P, Hernádi Z, et al: Elevated human epididymis protein 4 concentrations in chronic kidney disease. Ann Clin Biochem 2012;49(pt 4):377-380.
- Partridge E, Kreimer AR, Greenlee RT, et al: Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol 2009;113:775-782.
- Escudero JM, Auge JM, Filella X, Torne A, Pahisa J, Molina R: Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin Chem 2011;57:1534-1544.
- Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, et al: Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol 2008;110:196-201.
- Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, Drescher CW, et al: Use of a symptom index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol 2010;116:378-383.
- Park Y, Lee JH, Hong DJ, Lee EY, Kim HS: Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases. Clin Biochem 2011;44:884-888.
- Hellström I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, et al: The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63:3695-3700.
- Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, Davies AP, et al: Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999;353:1207-1210.
- Ghasemi N, Ghobadzadeh S, Zahraei M, Mohammadpour H, Bahrami S, Ganje MB, Rajabi S: HE4 combined with CA125: favorable screening tool for ovarian cancer. Med Oncol 2014;31:808.
- Anastasi E, Granato T, Falzarano R, Storelli P, Ticino A, Frati L, et al: The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer. J Ovarian Res 2013;6:44.
- Hamed EO, Ahmed H, Sedeek OB, Mohammed AM, Abd-Alla AA, Abdel Ghaffar HM: Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response. Diagn Pathol 2013;8:11.
- Partheen K, Kristjansdottir B, Sundfeldt K: Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass. J Gynecol Oncol 2011;22:244-252.
Article / Publication Details
Received: August 31, 2015
Accepted: November 05, 2015
Published online: April 29, 2016
Issue release date: September 2016
Number of Print Pages: 6
Number of Figures: 3
Number of Tables: 3
ISSN: 0378-7346 (Print)
eISSN: 1423-002X (Online)
For additional information: https://www.karger.com/GOI
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
